ASCO/EHA/ICML 2021 – Alvaro Alencar

Alvaro Alencar discusses which first-line treatment options might soon be established for newly diagnosed patients with mantle cell lymphoma who are not eligible for intensive therapy, what can be expected in terms of innovative approaches in the setting of R/R mantle cell lymphoma or marginal zone lymphoma and highlights the need for robust prognostic tools allowing stratification of treatment modalities.

Here is the full ASCO/EHA/ICML 2021 report.